Add-on dapagliflozin improves outcomes in uncontrolled T2D
Patients with type 2 diabetes (T2D) uncontrolled on current insulin therapy may benefit from adjunctive dapagliflozin, which has been shown to enhance glycaemic control and additionally lead to weight loss, reduction in insulin requirement, and fewer hypoglycaemic events.